BrightInsight today announced a new investment round of $13 million from existing and new investors including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners. This new capital will accelerate development of BrightInsight's AI-enabled medication persistence and adherence solutions and enable rapid scalability of high-impact programs, such as the Patient App from its collaboration with Sanofi and their partner, Regeneron, across a broad range of diseases and therapies globally..

BrightInsight 今天宣布了一轮 1300 万美元的新融资，来自现有投资者和新投资者，包括 Eclipse、General Catalyst、Insight Partners、梅奥诊所和 New Leaf Venture Partners。这笔新资金将加速 BrightInsight 的人工智能驱动的药物持续性和依从性解决方案的开发，并使其高影响力的项目能够快速扩展，例如与赛诺菲及其合作伙伴再生元合作开发的患者应用程序，覆盖全球范围内的多种疾病和治疗领域。

BrightInsight is the trusted partner and de-facto platform for top biopharma compliant digital health solutions. For life sciences companies pursuing digital transformation, the company offers the leading technology to rapidly develop, launch, and scale digital solutions. BrightInsight's cloud-based platform is the foundation for patient companion apps, digital-first patient support programs (PSP) and Software as a Medical Device (SaMD) solutions to improve medication persistence and adherence..

BrightInsight 是顶级生物制药合规数字健康解决方案的可信合作伙伴和事实上的平台。对于追求数字化转型的生命科学公司，该公司提供领先的技术，以快速开发、发布和扩展数字解决方案。BrightInsight 基于云的平台是患者伴侣应用程序、以数字为先的患者支持计划 (PSP) 以及作为医疗器械的软件 (SaMD) 解决方案的基础，旨在提高药物的持续性和依从性。